secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2021-12-09T23:59:59+00:00
Accession:  0001104659-21-147884
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics appoints Katharine Knobil, M.D., to Board of Directors
--------------------------------------------------------------------------

- Appointment effective December 8, 2021; Dr. Knobil will serve until 2022 annual meeting.
- Annual cash compensation of $40,000 paid quarterly; initial option for 125,000 shares vesting monthly over three years.
- Dr. Knobil brings 20 years of leadership at GlaxoSmithKline; currently CMO at Agilent Technologies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465921147884/0001104659-21-147884-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465921147884/tm2134930d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-147884

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer